710 related articles for article (PubMed ID: 17610276)
1. Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.
Bagi CM; Volberg M; Moalli M; Shen V; Olson E; Hanson N; Berryman E; Andresen CJ
Anat Rec (Hoboken); 2007 Aug; 290(8):1005-16. PubMed ID: 17610276
[TBL] [Abstract][Full Text] [Related]
2. The effects of bone remodeling inhibition by alendronate on three-dimensional microarchitecture of subchondral bone tissues in guinea pig primary osteoarthrosis.
Ding M; Danielsen CC; Hvid I
Calcif Tissue Int; 2008 Jan; 82(1):77-86. PubMed ID: 18175032
[TBL] [Abstract][Full Text] [Related]
3. Effect of eicosapentaenoic acid on bone changes due to methylprednisolone in rats.
Shomali T; Rezaian M; Rassouli A; Asadi F
Basic Clin Pharmacol Toxicol; 2009 Jul; 105(1):46-50. PubMed ID: 19302435
[TBL] [Abstract][Full Text] [Related]
4. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.
Christiansen P
APMIS Suppl; 2001; (102):1-52. PubMed ID: 11419022
[TBL] [Abstract][Full Text] [Related]
5. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis.
Seeman E
Osteoporos Int; 2003; 14 Suppl 3():S2-8. PubMed ID: 12730770
[TBL] [Abstract][Full Text] [Related]
6. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.
Chavassieux PM; Arlot ME; Reda C; Wei L; Yates AJ; Meunier PJ
J Clin Invest; 1997 Sep; 100(6):1475-80. PubMed ID: 9294113
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
Feher A; Koivunemi A; Koivunemi M; Fuchs RK; Burr DB; Phipps RJ; Reinwald S; Allen MR
Bone; 2010 Jan; 46(1):203-7. PubMed ID: 19857619
[TBL] [Abstract][Full Text] [Related]
8. [Effects of bisphosphonates on the mechanical efficiency of normal and osteopenic bones].
Ferretti JL; Cointry GR; Capozza RF; Mondelo N; Peluffo V; Chiappe A; Meta M; Alippi RM
Medicina (B Aires); 1997; 57 Suppl 1():83-92. PubMed ID: 9567360
[TBL] [Abstract][Full Text] [Related]
9. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.
Ma YL; Zeng Q; Donley DW; Ste-Marie LG; Gallagher JC; Dalsky GP; Marcus R; Eriksen EF
J Bone Miner Res; 2006 Jun; 21(6):855-64. PubMed ID: 16753016
[TBL] [Abstract][Full Text] [Related]
10. The effects of alendronate on bone turnover and bone quality.
Meunier PJ; Arlot M; Chavassieux P; Yates AJ
Int J Clin Pract Suppl; 1999 Apr; 101():14-7. PubMed ID: 12669736
[TBL] [Abstract][Full Text] [Related]
11. Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.
Geoffroy V; Paschalis EP; Libouban H; Blouin S; Ostertag A; Chappard D; Cros M; Phipps R; de Vernejoul MC
Calcif Tissue Int; 2011 Jun; 88(6):464-75. PubMed ID: 21455736
[TBL] [Abstract][Full Text] [Related]
12. Human parathyroid hormone 1-34 prevents bone loss in experimental biliary cirrhosis in rats.
Dresner-Pollak R; Gabet Y; Steimatzky A; Hamdani G; Bab I; Ackerman Z; Weinreb M
Gastroenterology; 2008 Jan; 134(1):259-67. PubMed ID: 18061175
[TBL] [Abstract][Full Text] [Related]
13. Age- and menopause-related bone loss compromise cortical and trabecular microstructure.
Seeman E
J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1218-25. PubMed ID: 23833200
[TBL] [Abstract][Full Text] [Related]
14. Overview: animal models of osteopenia and osteoporosis.
Jee WS; Yao W
J Musculoskelet Neuronal Interact; 2001 Mar; 1(3):193-207. PubMed ID: 15758493
[TBL] [Abstract][Full Text] [Related]
15. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
16. Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities.
Steiniche T
APMIS Suppl; 1995; 51():1-44. PubMed ID: 7669370
[TBL] [Abstract][Full Text] [Related]
17. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
18. Is cortical bone hip? What determines cortical bone properties?
Epstein S
Bone; 2007 Jul; 41(1 Suppl 1):S3-8. PubMed ID: 17466615
[TBL] [Abstract][Full Text] [Related]
19. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
Kostenuik PJ; Smith SY; Samadfam R; Jolette J; Zhou L; Ominsky MS
J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
[TBL] [Abstract][Full Text] [Related]
20. [The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model].
Wang X; Yang Z; Yu S
Zhonghua Kou Qiang Yi Xue Za Zhi; 2001 May; 36(3):193-6. PubMed ID: 11812340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
